Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).

George  Lau

Employment - Humanity & Health Medical Group

Leadership - Humanity & Health Medical Group

Consulting or Advisory Role - AstraZeneca

Ann-Lii  Cheng

Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche

Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Ono Pharmaceutical; Roche

Bruno  Sangro

Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; Eisai; Incyte; Ipsen; Roche/Genentech; Sirtex Medical; TERUMO

Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; Incyte; Ipsen; Roche; Sirtex Medical

Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst); Sirtex Medical (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Eisai; Roche; Sirtex Medical

Masatoshi  Kudo

Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda

Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai

Research Funding - Abbvie (Inst); Chugai/Roche (Inst); EA Pharma (Inst); Eisai (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)

Robin Kate  Kelley

Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Exelixis/Ipsen (Inst); Kinnate Biopharma; Merck (Inst); Regeneron; Tyra Biosciences

Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)

Travel, Accommodations, Expenses - AstraZeneca

Won Young  Tak

No Relationships to Disclose

Antonio  Gasbarrini

Honoraria - Abbvie; Alfasigma; Lion Health; MSD; Roche; Sanofi; Takeda

Consulting or Advisory Role - Abbvie; Alfasigma; Lion Health; MSD; Roche; Sanofi; Takeda

Maria  Reig

No Relationships to Disclose

Ho Yeong  Lim

Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai

Speakers' Bureau - Bayer

David  Tougeron

Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; Servier/Pfizer

Consulting or Advisory Role - AstraZeneca; MSD; Novartis; Pierre Fabre; Sanofi

Research Funding - AstraZeneca (Inst); BTG (Inst); MSD (Inst); Roche (Inst); SERVIER (Inst)

Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Sanofi

Enrico N.  De Toni

Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO

Research Funding - AstraZeneca; Bayer; Bristol-Myer Squibb; Ipsen; Lilly; Roche

Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion; IPSEN; Roche

Vincent C.  Tam

Honoraria - AstraZeneca; Eisai; Incyte; Ipsen; Roche Canada

Research Funding - AstraZeneca (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Merck (Inst); Roche Canada (Inst)

Expert Testimony - AstraZeneca Canada; Incyte

Kabir  Mody

Employment - IMV

Stock and Other Ownership Interests  - CytoDyn; IMV; Oncotherapeutics

Consulting or Advisory Role - AstraZeneca; Boston Scientific; BTG; BTG; Celgene; Eisai; Exelixis; Exelixis; Genentech/Roche; Incyte (Inst); Ipsen; Merrimack; QED Therapeutics; Vicus Therapeutics

Research Funding - Agios (Inst); ARIAD (Inst); ArQule (Inst); AstraZeneca (Inst); Basilea (Inst); FibroGen (Inst); Gritstone Bio (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); TRACON Pharma (Inst); Turnstone Bio (Inst); Vyriad (Inst)

Jun  Gong

Honoraria - Amgen; Astellas Pharma; AVEO; Basilea Pharmaceutical; Bayer; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono; Exelixis; HalioDx; Incyte; Janssen Biotech; Natera; Pfizer/Myovant; QED Therapeutics

Consulting or Advisory Role - Amgen; Astellas Pharma; AVEO; Basilea; Bayer; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono/Merck; Exelixis; HalioDx; Incyte; Janssen Biotech; MJH Life Sciences; Natera; OncLive/MJH Life Sciences; Pfizer/Myovant; QED Therapeutics; Seagen

Patents, Royalties, Other Intellectual Property - PCT/US2021/043961 provisional patent on glutamine and cancer; U.S. Provisional Application Serial No. 63/315,895 on methylated ctDNA markers

Carrie L.  McCoy

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Charu  Gupta

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Mallory  Makowsky

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Alejandra  Negro

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Ghassan K.  Abou-Alfa

Consulting or Advisory Role - AstraZeneca; Autem Medical; Boehringer Ingelheim (I); Eisai; Exelixis; Helio Health; Incyte; Ipsen; Merck Serono; Newbridge Pharmaceuticals; Novartis (I); QED Therapeutics; Roche/Genentech; SERVIER; Yiviva

Research Funding - Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)